Ascorbic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ascorbic Acid: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation
One-Sentence Summary
Ascorbic acid (Vitamin C) is an essential water-soluble micronutrient, established for the prevention and treatment of scurvy (Vitamin C deficiency) and widely used as a nutritional supplement and adjunctive therapy across many clinical settings. The TxGNN model predicts it may be effective for Non-Syndromic Esophageal Malformation, with 0 clinical trials and 0 publications currently supporting this direction. The evidence base for this specific predicted indication is absent, and the mechanistic rationale is considered extremely weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No UK marketing authorisation records found in current database; known primary use is prevention and treatment of Vitamin C deficiency (Scurvy) |
| Predicted New Indication | Non-Syndromic Esophageal Malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| UK Market Status | No UK marketing authorisations found in current database |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the system. Based on well-established pharmacological knowledge, Ascorbic acid (Vitamin C) is a potent antioxidant and a cofactor for prolyl hydroxylase and lysyl hydroxylase enzymes — both essential for the post-translational hydroxylation of collagen precursors. This role in collagen biosynthesis underpins its established therapeutic use in scurvy, a disease of defective connective tissue.
The theoretical link to non-syndromic esophageal malformation arises from this collagen synthesis pathway: normal embryonic oesophageal structural development requires adequate extracellular matrix formation, and collagen is central to oesophageal wall integrity. Severe Vitamin C deficiency during a critical developmental window could, in principle, impair this process. The TxGNN knowledge graph likely captures this broad Ascorbic acid → collagen → connective tissue → structural development relationship.
However, the mechanistic link is extremely weak and the clinical plausibility very low. Non-syndromic esophageal malformation is a congenital structural anomaly arising from aberrant embryogenesis — it is not a nutritional deficiency disorder, and there is no clinical or basic research evidence to support Ascorbic acid as a preventive or therapeutic agent for this condition. This prediction should be regarded as a knowledge graph artefact rather than a genuine drug repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation records were identified for Ascorbic acid in the current regulatory data feed.
Note for clinicians: Ascorbic acid is in practice widely available on the UK market — as over-the-counter nutritional supplements, as a component of licensed parenteral nutrition preparations, and in various licensed oral formulations. The absence of records here reflects a gap in the current regulatory database rather than true non-availability. Clinicians should consult the MHRA Product Licence Register and the BNF for current authorised products and indications.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Although TxGNN assigns a high prediction score (99.96%), non-syndromic esophageal malformation is a congenital structural anomaly with no clinical or preclinical evidence supporting Ascorbic acid as a relevant intervention; the mechanistic link is indirect and speculative, and evidence is classified L5 (model prediction only, no supporting studies). Further resource investment is not justified at this stage.
To proceed, the following is needed:
- Preclinical evidence (in vitro embryonic models or animal developmental studies) establishing whether Ascorbic acid deficiency or supplementation meaningfully affects oesophageal structural development
- Identification of a specific, mechanistically credible molecular pathway linking Ascorbic acid to the known pathogenesis of non-syndromic esophageal malformation
- Detailed mechanism of action data for Ascorbic acid sourced from DrugBank API (currently a data gap)
- Verification of UK regulatory status via the MHRA product licence register and BNF to confirm currently authorised indications and formulations
- Safety data retrieval from the MHRA and SmPC to enable formal S1 safety assessment before any clinical feasibility work
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.